Physician profile
John Michael Smith
NPI 1316971757
$153,262.93
in general payments reported to CMS, 2019-2025
15 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $39K · 2021: $35K · 2022: $21K · 2023: $13K · 2024: $4,480 · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Travel and Lodging: $4,775 · Food and Beverage: $2,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Travel and Lodging | $4,774.63 |
| Food and Beverage | $2,981.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $118,593.28 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System, Atriclip Laa Exclusion System |
| Intuitive Surgical, INC. | $16,341.17 | 2019-2025 | |
| Biostable Science & Engineering | $13,200.00 | 2020 | |
| Artivion, INC. | $2,452.41 | 2024-2025 | Cardiac Non-Synergraft, Cryovalve Sg Pulmonary Human Heart Valve |
| Abbott Laboratories | $1,061.98 | 2020-2023 | Mitraclip |
| Edwards Lifesciences Corporation | $951.72 | 2019-2023 | |
| Medtronic, INC. | $194.09 | 2022-2024 | Penditure |
| Kls-Martin L.P. | $174.00 | 2021 | |
| Medistim USA, INC. | $119.60 | 2021 | |
| Livanova USA, INC. | $96.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2024 | Entyvio |
| Getinge USA Sales, LLC | $22.05 | 2020 | |
| Legacy Ortho LLC | $16.40 | 2024 | |
| Solventum Corporation | $15.37 | 2024 | V.A.C. Veraflo, V.A.C. Veraflo Cleanse Choice, Prevena |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.